Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
21.30
-0.30 (-1.39%)
At close: Dec 26, 2025, 4:00 PM EST
21.15
-0.15 (-0.71%)
After-hours: Dec 26, 2025, 7:16 PM EST
Syndax Pharmaceuticals Revenue
Syndax Pharmaceuticals had revenue of $45.87M in the quarter ending September 30, 2025, with 266.97% growth. This brings the company's revenue in the last twelve months to $111.55M, up 597.19% year-over-year. In the year 2024, Syndax Pharmaceuticals had annual revenue of $23.68M.
Revenue (ttm)
$111.55M
Revenue Growth
+597.19%
P/S Ratio
16.56
Revenue / Employee
$412,237
Employees
270
Market Cap
1.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23.68M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 139.71M | 138.19M | 9,109.56% |
| Dec 31, 2020 | 1.52M | - | - |
| Dec 31, 2019 | 1.52M | - | - |
| Dec 31, 2018 | 1.52M | -591.00K | -28.04% |
| Dec 31, 2017 | 2.11M | 888.00K | 72.79% |
| Dec 31, 2016 | 1.22M | 593.00K | 94.58% |
| Dec 31, 2015 | 627.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SNDX News
- 10 days ago - Syndax Pharma: Continuing Execution In AML - Seeking Alpha
- 15 days ago - Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025 - GlobeNewsWire
- 19 days ago - Syndax Pharmaceuticals, Inc. (SNDX) Presents at The 67th American Society of Hematology (ASH) Annual Meeting Transcript - Seeking Alpha
- 19 days ago - Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum - GlobeNewsWire
- 24 days ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 26 days ago - Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth - Seeking Alpha
- 6 weeks ago - Syndax Pharmaceuticals, Inc. (SNDX) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha